| Target Price | A$332.34 |
| Price | A$251.83 |
| Potential |
31.97%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Pro Medicus 2026 .
The average Pro Medicus target price is A$332.34.
This is
31.97%
register free of charge
A$367.50
45.93%
register free of charge
A$292.90
16.31%
register free of charge
|
|
| A rating was issued by 17 analysts: 8 Analysts recommend Pro Medicus to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pro Medicus stock has an average upside potential 2026 of
31.97%
register free of charge
|
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million A$ | 220.54 | 286.93 |
| 32.59% | 30.10% | |
| EBITDA Margin | 78.21% | 79.58% |
| 3.13% | 1.75% | |
| Net Margin | 52.24% | 54.07% |
| 4.96% | 3.49% |
15 Analysts have issued a sales forecast Pro Medicus 2026 . The average Pro Medicus sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Pro Medicus EBITDA forecast 2026. The average Pro Medicus EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Pro Medicus Analysts have issued a net profit forecast 2026. The average Pro Medicus net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Jun '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | 1.10 | 1.49 |
| 39.24% | 35.45% | |
| P/E | 171.25 | |
| EV/Sales | 93.95 |
15 Analysts have issued a Pro Medicus forecast for earnings per share. The average Pro Medicus EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WILSONS |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| MOELIS AUSTRALIA SECURITIES |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| E&P |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
WILSONS:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
MOELIS AUSTRALIA SECURITIES:
Locked
➜
Locked
|
Sep 16 2025 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
E&P:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Jul 17 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


